Cargando…
Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
Anti-thymocyte globulin (ATG) is a lymphocyte depleting agent applied in hematopoietic stem cell transplantation (HSCT) to prevent rejection and Graft-vs.-Host Disease (GvHD). In this study, we compared two rabbit ATG products, ATG-Genzyme (ATG-GENZ), and ATG-Fresenius (ATG-FRES), with respect to do...
Autores principales: | Oostenbrink, Lisa V. E., Jol-van der Zijde, Cornelia M., Kielsen, Katrine, Jansen-Hoogendijk, Anja M., Ifversen, Marianne, Müller, Klaus G., Lankester, Arjan C., van Halteren, Astrid G. S., Bredius, Robbert G. M., Schilham, Marco W., van Tol, Maarten J. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414431/ https://www.ncbi.nlm.nih.gov/pubmed/30894854 http://dx.doi.org/10.3389/fimmu.2019.00315 |
Ejemplares similares
-
Development and Validation of an Efficient and Highly Sensitive Enzyme-Linked Immunosorbent Assay for Alemtuzumab Quantification in Human Serum and Plasma
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023) -
Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme
por: Wang, Lu, et al.
Publicado: (2023) -
Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023) -
Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
por: Counsilman, Clare E., et al.
Publicado: (2015) -
Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)